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Introduction
Cytogenetic and molecular alterations at diagnosis and response to treatment are
the most useful criteria for predicting the relative risk of relapse in acute myeloid
leukemia (AML), and for guiding the choice between chemotherapy and
Ahigh proportion of patients with acute myeloid leukemia whoachieve minimal residual disease negative status ultimately relapsebecause a fraction of pathological clones remains undetected by
standard methods. We designed and validated a high-throughput sequenc-
ing method for minimal residual disease assessment of cell clonotypes with
mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For
clinical validation, 106 follow-up samples from 63 patients in complete
remission were studied by sequencing, evaluating the level of mutations
detected at diagnosis. The predictive value of minimal residual disease sta-
tus by sequencing, multiparameter flow cytometry, or quantitative poly-
merase chain reaction analysis was determined by survival analysis. The
sequencing method achieved a sensitivity of 10-4 for single nucleotide vari-
ants and 10-5 for insertions/deletions and could be used in acute myeloid
leukemia patients who carry any mutation (86% in our diagnostic data set).
Sequencing–determined minimal residual disease positive status was asso-
ciated with lower disease-free survival (hazard ratio 3.4, P=0.005) and
lower overall survival (hazard ratio 4.2, P<0.001). Multivariate analysis
showed that minimal residual disease positive status determined by
sequencing was an independent factor associated with risk of death (haz-
ard ratio 4.54, P=0.005) and the only independent factor conferring risk of
relapse (hazard ratio 3.76, P=0.012). This sequencing-based method simpli-
fies and standardizes minimal residual disease evaluation, with high appli-
cability in acute myeloid leukemia. It is also an improvement upon flow
cytometry- and quantitative polymerase chain reaction-based prediction of
outcomes of patients with acute myeloid leukemia and could be incorpo-
rated in clinical settings and clinical trials.
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ABSTRACT
hematopoietic stem cell transplantation in first complete
remission.1 The definition of complete remission for AML
includes criteria for the identification of patients with
poor prognosis using cytomorphological methods,2 but
these studies do not have a good predictive value because
most of the patients in complete remission relapse within
3 years of diagnosis.3
Assessment of minimal residual disease (MRD) is critical
in monitoring patients in morphological remission, to
inform decisions about further therapy.1 Indeed, several
studies have reported MRD status as a stronger predictor
of relapse, because patients who are MRD negative have
a better prognosis than those who are MRD positive.4,5 In
support of this, recent non-randomized studies from
prospective multicenter trials suggested better outcomes
when leukemia therapy was selected based on the results
of MRD assessment.6-8
AML is, nevertheless, a biologically complex and het-
erogeneous disease, which makes MRD testing more chal-
lenging in this condition than in other hematologic neo-
plasms such as acute lymphoblastic leukemia or multiple
myeloma. The detection of very low levels of MRD by
conventional methods such as quantitative (q) polymerase
chain reaction (PCR) or multiparameter flow cytometry
(MFC) provides powerful independent prognostic infor-
mation. Unfortunately, as described for cytomorphologi-
cal complete remission, many patients who achieve MRD
negative status relapse as a result of the progression of
undetected leukemic cells. The most common method for
MRD detection is MFC, which has intermediate applica-
bility (70–80%) and limited sensitivity.9,10 However, there
is no consensus on multi-antibody panels with regards to
inter-laboratory performance, and the technique requires a
high level of expertise. The other principal method for
monitoring MRD, qPCR, has good sensitivity (10-4-10-6),
but its applicability is limited to the approximately 40% of
patients who present with molecular alterations (RUNX1-
RUNX1T1, CBFβ-MYH11 or NPM1) at diagnosis.11
For the above reasons, new methods with higher sensi-
tivity, specificity, applicability and performance are need-
ed for MRD assessment in AML. Against this background,
next-generation sequencing (NGS) and digital PCR (dPCR)
have recently emerged as potentially promising platforms
for the assessment of MRD.12 Here, we optimized and
clinically validated a new deep targeted NGS-based
method, supported with dPCR technical validation, for
the detection and quantification of MRD [both small
insertion/deletions (indels) and single nucleotide variants
(SNV)] in AML patients, in an attempt to improve and/or
complement the current techniques for MRD evaluation,
and to establish its potential as a predictor of patients’ out-
come.
Methods
More detailed information can be found in the Online
Supplementary Data (1–6).
Patients and samples
One hundred and ninety patients with de novo or secondary
non–M3 AML were included in mutational profile screening at
diagnosis. We performed a new selection for retrospective MRD
assessment using the following criteria: presence of the NPM1
type A mutation, or SNV in FLT3, IDH1 and/or IDH2 at diagno-
sis, and availability of at least one follow-up genomic (g)-DNA
sample. 
The MRD approach was applied to 51 (48%) follow-up sam-
ples taken after induction therapy and 55 (52%) taken after con-
solidation, corresponding to 63 patients diagnosed between 2006
and 2016 (for selection criteria see Online Supplement 6 and
Supplementary Table S1). Patients were treated according to
PETHEMA (Programa Español de Tratamientos en Hematología) or
CETLAM (Grupo cooperativo de Estudio y Tratamiento de Leucemias
Agudas y Mielodisplasias) protocols. The study was conducted
according to Spanish law 14/2007 on biomedical research, and
was approved by the Research Ethics Board of each participating
institution. All patients provided informed consent. The main
clinical characteristics of the patients are summarized in Table 1.
All patients achieved complete remission according to cytomor-
phological criteria after induction therapy (<5% of bone marrow
blasts). 
To construct calibration curves, commercial (Horizon
Discovery, UK) reference standard gDNA was used for somatic
SNV in IDH1 (R132C) and IDH2 (R172K). As a further source of
gDNA, we used the OCI-AML3 cell line (ACC 582, DSMZ,
Germany) with the NPM1 type A mutation
(c.863_864insCCTG) to examine indels. As OCI-AML3 cells also
present a SNV in DNMT3A (R882C), this was included only for
technical optimization.
Deep targeted sequencing workflow
The sequencing workflow included a first study at diagnosis
and a second study at follow-up. Mutational profile screening at
diagnosis was done with a customized NGS myeloid panel of 32
genes frequently mutated in myeloid diseases,13 (Online
Supplementary Table S2) and NPM1 analysis was carried out with
qPCR.14
The specific mutations detected at diagnosis were studied at fol-
low-up. We first tested a variety of experimental steps to define
optimal conditions (Online Supplement 1). We established an opti-
mal protocol (Figure 1) that included DNA amplification, library
preparation and sequencing as experimental steps (Online
Supplement 2).  
Libraries were sequenced on the Ion Proton System platform
(Life Technologies, Thermo Fisher Scientific Inc.) with an estimat-
ed depth ≥1,000,000 of reads, generating .fastq files. These files
were analyzed using a customized bioinformatic pipeline; which
leads from the .fastq file and a .csv file that contains information
about name identifier, run and barcode identifier, chromosomal
position and the variant detected in the diagnosis to be evaluated
in the follow-up sample. Through Ensembl Perl API,15 the aligned
mutated sequence and the aligned wild-type (wt) sequence are
presented in FASTA format (sequences of 40 bp). Finally, we
obtained a .csv file containing the name identifier, run and barcode
identifier, chromosomal position, the variant, the specific target
sequence in FASTA format (mutated forward, mutated reverse, wt
forward and wt reverse), the counts of each and the ratio (mutat-
ed/wt) in absolute values.
Results
A high percentage of acute myeloid leukemia patients
could benefit from deep sequencing minimal residual
disease assessment
In total, 211 (80%) SNV and 46 (20%) indels were
detected in the 190 patients analyzed at diagnosis using
the customized NGS panel. We detected one variant (SNV
or indel) in 48 (25%) cases, two or more variants in 116
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(61%) cases and no variants in 26 (14%) cases. In addition,
we detected the NPM1 type A mutation in 53 (28%)
patients by qPCR. Genes (TET2, ASXL1, or DNMT3A)
with evidence of an association with clonal hematopoiesis
of indeterminate potential (CHIP) were excluded from the
analysis.11 Consequently, 82% of patients in our cohort
could benefit from this approach. 
Based on those genes reported as potential markers for
monitoring MRD,16 and also the availability of follow-up
samples, we focused on IDH1/2 and FLT3-SNV. We iden-
tified at diagnosis IDH1 mutations in 13 patients (7%),
IDH2 mutations in 27 patients (14%) and FLT3-SNV
mutations (18%) in 34 patients.
Deep sequencing minimal residual disease assessment
has a sensitivity of 10-4 for single nucleotide variants
and 10-5 for insertions-deletions
To establish the limit of quantification (LOQ) of the
method, we used 10-fold serial dilutions of mixed mutat-
ed and control DNA. To study prototype indels, we used
gDNA from OCI-AML3 cells (NPM1 type A) and to study
prototype SNV, we used both gDNA from OCI-AML3
cells (DNMT3A) and commercial reference gDNA
(IDH1/IDH2). As a control, we used a pool of gDNA from
ten individuals without somatic mutations in these chro-
mosomal regions. In all cases, initial allele frequency was
50% and a total of six dilutions were tested to construct a
calibration curve, covering a theoretical dynamic range
from 10-1 to 10-7. 
As shown in Figure 2A,B, MRD NGS testing of NPM1
(indel) could quantify one mutated cell in the order of 10-5
normal ones and in the case of SNV (IDH1, IDH2 and
DNMT3A) the LOQ was 10-4, which was reproducible for
all SNV tested.
Next-generation sequencing is more sensitive than 
digital polymerase chain reaction analysis for minimal
residual disease assessment
We compared the sensitivity of the sequencing method
with that of dPCR using the same LOQ dilution protocol.
Clone frequency expressed as target concentration (mutat-
ed copies/mL in wt copies/mL) gradually decreased with
each dilution, reaching a LOQ of 10-3 for NPM1, IDH1 and
IDH2 (Figure 2C,D). While both methods showed similar
detection limits and good linearity, the LOQ for the
sequencing method was one order of magnitude higher
than that for dPCR (IDH1 and IDH2), and two orders of
magnitude higher for indels (NMP1).
Minimal residual disease status assessed 
by sequencing has prognosis value in acute 
myeloid leukemia 
The median depth coverage was 401,300 aligned reads
(interquartile range 195,100–825,700) for the 88 NPM1 and
18 SNV (9 IDH1, 7 IDH2, and 2 FLT3) follow-up samples
evaluated. We detected no mutated sequence in 13 (12%)
samples, one to five mutated sequences in 19 (18%) sam-
ples, and more than ten in 74 (70%) samples. The ratio of
mutated sequences to wt sequences defined MRD levels.
Considering MRD levels from the 106 samples evaluated
we established the optimal cutoff to classify MRD status
(positive versus negative) by receiver operating characteristic
curves (Online Supplementary Figure S1) at each check-point
of MRD evaluation [post-induction (n=51), post-consolida-
tion (n=55), or both together (n=106)]. 
Survival analysis revealed that positive MRD status
(MRD levels >0.1%) after induction (n=35) was associat-
ed with a significantly lower rate of overall survival
[33% versus 78%; hazard ratio (HR): 3.5; 95% confidence
interval (CI): 1.1–10.7; P=0.019], but a non-significant
lower rate of disease-free survival (58% versus 78%; HR:
2.18; 95% CI: 0.63–7.5; P=0.208) (Figure 3A,B). In post-
consolidation samples (n=28), MRD positive status
E. Onecha et al.
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Table 1. Main characteristics of the patients with acute myeloid
leukemia included in the minimal residual disease study.
Patients (n = 63)
Follow-up sample type                                                          
Bone marrow                                                               58 (92%)
Peripheral blood                                                           5 (8%)
Sex                                                                                             
Male                                                                               21 (33%) 
Female                                                                           42 (67%)
Age at diagnosis, median                                    54 (IQR, 41.5–66.0)
                                                                                                   
Blasts at diagnosis, median count                   69 (IQR, 51.0–81.0)
                                                                                                   
Leukocytes at diagnosis                                   15.7 (IQR,12.2–20.24)
median count (×109/L)                                                         
Secondary AML                                                                      
No                                                                                   59 (94%) 
Yes                                                                                   4 (6%) 
Cytogenetic risk                                                                     
Favorable                                                                       25 (40%)
Intermediate                                                                 36 (57%) 
Adverse                                                                           2 (3%)
FLT3-ITD                                                                                   
FLT3 negative                                                               49 (78%)
FLT3 positive                                                                 14 (22%)
FLT3-TKD
FLT3 negative                                                               60 (95%)
FLT3 positive                                                                   3 (5%)
NPM1
NPM1 negative                                                              6 (10%)
NPM1 positive                                                              57 (90%)
Hematopoietic stem cell transplantation                        
No                                                                                   42 (67%) 
Allogeneic                                                                      7 (11%) 
Autologous                                                                    14 (22%)
Relapse                                                                                     
No                                                                                   42 (67%) 
Yes                                                                                   21 (33%)
Death                                                                                         
No                                                                                   40 (63%) 
Yes                                                                                   23 (37%)
Treatment*                                                                             
3+7 regimen                                                                 50 (80%) 
Flugaza                                                                            8 (13%)
Mylotarg                                                                           2 (3%)
Panobidara                                                                      3 (4%)
AML: acute myeloid leukemia; ITD: internal tandem duplications; TKD: tyrosine kinase
domain; *3+7 regimen of chemotherapy: one or two induction cycles of cytarabine
and idarubicin for 7 and 3 days, respectively; and two or three consolidation cycles of
high doses of cytarabine, twice a day for 3 alternate days followed by allogeneic or
autologous hematopoietic stem cell transplantation. The remainder of the patients
were included in other clinical trials (Mylotarg, NTC0104104; Flugaza, NCT02319135;
Panobidara, NCT00840346). Clinical data were collected in the following Spanish AML
epidemiological registries: NCT01700413, NCT02006004, NCT00464217, NCT02607059,
NCT01041040 and NCT01296178.
(MRD levels >0.025%) was associated with both signifi-
cantly shorter overall survival (33% versus 81%; HR: 6.0;
95% CI: 1.3–28.7; P<0.001) and significantly shorter dis-
ease-free survival (17% versus 94%; HR: 19.6; 95% CI:
2.5–155.6; P<0.001) (Figure 3C,D). Survival outcomes
were also analyzed combining post-induction and post-
consolidation (n=63) tests, in order to compare survival
analysis with MFC and qPCR data sets. We observed
that positive MRD status (MRD levels >0.035%) was
associated with a higher risk of relapse (48% versus 81%;
HR: 3.4; 95% CI: 1.4–8.5; P=0.005) and death (37% ver-
sus 81%; HR: 4.2; 95% CI: 1.6–10.7; P<0.001) (Figure
3E,F). In order to test the power of NPM1 and SNV as
independent predictive markers, we performed the
analysis separately. Evaluating NPM1 as an MRD marker
(n=54), we found that MRD positive status was associat-
ed with both significantly shorter overall survival (43%
versus 78%; HR: 3.3; 95% CI: 1.2–8.8; P=0.011), and
shorter disease-free survival (57% versus 85%; HR: 2.9;
95% CI: 0.9–7.6; P=0.052). Similar results were found
when we evaluated IDH1, IDH2 or FLT3-SNV as MRD
markers (n=11). Accordingly, MRD positive status was
associated with both significantly shorter overall survival
(17% versus 100%; HR: not applicable; P=0.041), and
shorter disease-free survival (17% versus 75%; HR: 6.3;
95% CI:0.7–54; P=0.058).
In univariate Cox analysis (Table 2A), the risk of death
was significantly higher with increasing age (HR: 1.04;
P=0.013), in patients with FLT3-ITD (HR: 3.45; P=0.007),
and in those with MRD positive status as determined by
NGS (HR: 4.22; P=0.002). The risk of relapse was signifi-
cantly higher only in those patients with MRD positive
status determined by NGS (HR: 3.4; P=0.008). In multi-
variate analysis (Table 2B), the risk of death was signifi-
cantly higher with increasing age (HR: 1.05; P=0.004), in
patients with mutated FLT3-ITD (HR: 8.87; P=0.001), and
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Figure 1. Workflow of the
next-geneartion sequencing
– minimal residual disease
method.  DNA amplification,
library preparation and
sequencing experimental
workflow. Genomic DNA
(gDNA) is amplified by quanti-
tative (q) polymerase chain
reaction (PCR) using specific
primers. Libraries are pre-
pared in four steps: end
repair, adaptor ligation, size
selection, and PCR amplifica-
tion. The libraries are then
sequenced. A customized
bioinformatic pipeline ana-
lyzes the sequences
obtained. The results are
expressed as a ratio of
mutated sequences (mut)
among wild-type (wt)
sequences.
in those with MRD positive status determined by NGS
(HR: 4.54; P=0.005). The risk of relapse was higher only in
patients who were MRD positive as determined by NGS
(HR: 3.76; P=0.012).
Minimal residual disease assessment by sequencing
predicts overall survival and disease-free survival bet-
ter than multiparameter flow cytometry or quantitative
polymerase chain reaction analysis 
A positive correlation was found when comparing MRD
assessment by NGS versus MFC (r=0.47, P=0.005, n=75),
and NGS versus qPCR (r=0.62, P<0.001, n=80) (Online
Supplementary Figure S2). There were differences between
positive MRD and negative MRD groups of patients test-
ed by MFC, but they were not significant for either overall
survival (P=0.193) or disease-free survival (P=0.117) (n=46)
(Figure 4A). Similarly, differences were observed between
positive MRD and negative MRD groups defined by qPCR
of NPM1, although statistical significance was not reached
for either overall survival (P=0.212) or disease-free survival
(P=0.086) (n=46) (Figure 4B).
Discussion
We have optimized and validated a high sensitivity
NGS method for the detection and quantification of
NPM1, IDH1, IDH2 and FLT3-SNV mutated sequences at
very low allele frequency in follow-up gDNA samples.
NGS has demonstrated prognostic value for pre-treatment
status in patients with AML,17 and may also be a useful
tool for detecting MRD.18,19 We first studied the mutational
profile of patients with AML using a customized NGS
panel to ensure a high applicability (82% of patients). This
approach is also a useful screening method for detecting
all potential MRD markers and choosing those most rele-
vant. The combination of several markers is possible and
recommended to overcome limitations of MRD assess-
ment due to sub-clonal heterogeneity of AML and CHIP.11
Accordingly, our method has the capacity to evaluate mul-
tiple markers simultaneously and, considering that 61% of
patients in our cohort had two or more genetic alterations,
this approach is sufficiently robust to monitor MRD even
in patients with clonal evolution.
E. Onecha et al.
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Figure 2. Calibration curve of minimal residual disease in serial dilutions. (A,B) Ten-fold dilution curves for the assessment of the sensitivity of next-generation
sequencing (NGS) in (A) insertions-deletions (InDel), using OCI-AML3 gDNA with 50% NPM1 type A mutation (R2 = 0.98); and (B) single nucleotide variabts (SNV),
using OCI-AML3 gDNA with 50% mutated DNMT3A (R2 = 0.98), and gDNA with 50% mutated IDH1 or IDH2 from a commercial standard (R2 = 0.91 and R2 = 0.98,
respectively). (C,D) The same 10-fold dilution curves for the assessment of sensitivity of digital polymerase chain reaction (dPCR) in (C) InDel (R2 = 0.98); and (D)
SNV (R2 = 0.91 for IDH1 and R2 = 0.98 for IDH2). The vertical red bars indicate the limit of quantification (LOQ) according to the sample. Clone frequency is expressed
as target concentration as mutated copies/mL in wild-type copies/mL. Negative controls are included in the calibration curves and had levels below the corresponding
LOQ values.
A B
C D
Reported variants associated with CHIP are frequently
located in DNMT3A, TET2 or ASXL1 genes, and are
detected in the preleukemic phase and during complete
AML remission.20-23 Indeed, any gene could carry both
CHIP and non-CHIP variants, and these should be evalu-
ated for each patient. Moreover, studies have shown that
genes related to CHIP (IDH1/2) are useful for predicting
prognosis because in these cases the genetic alterations
have been acquired in the leukemic clone and not before.24
The sensitivity of this method equates to one mutated
cell per 100,000 cells (LOQ 10-5) for NPM1 and one mutat-
ed cell per 10,000 cells (LOQ 10-4) for IDH1, IDH2 and
FLT3-SNV. This difference in sensitivity is related to the
fact that the NPM1 type A mutation (insCCTG) is rarely
Deep sequencing method for MRD monitoring in AML
haematologica | 2019; 104(2) 293
Figure 3. Analysis of overall sur-
vival and disease-free survival
in patients with acute myeloid
leukemia stratified according
to minimal residual disease lev-
els determined by sequencing.
Analysis of overall survival for
(A) the induction data set, (C)
the consolidation data set, and
(C) both together. Analysis of
disease-free survival for (B) the
induction data set, (D) the con-
solidation data set, and (F) both
together. The cutoff used for
overall and disease-free survival
was 0.001 at the post–induc-
tion check-point (n=35),
0.00026 at the post-consolida-
tion check–point (n=28) and
0.00035 for both check-points
(all data set) (n=63). The num-
bers of censored patients with
respect to the stratified groups
and the numbers at risk are
indicated. Statistically signifi-
cant values: *P<0.05,
**P<0.01.
BA
DC
FE
generated erroneously by NGS, and the quantification is
precise. 
Our method, as with any NGS method, has an intrinsic
error rate that limits its sensitivity for most SNV to 1–2%
of all reads. This limitation can nevertheless be overcome
by virtue of the scalable nature of NGS.16 Thus, we boost-
ed NGS sensitivity by increasing the amount of DNA by
PCR prior to sequencing, which increased the depth of
coverage to one million reads. By also optimizing the
bioinformatic analysis, we focused the search for the pre-
cise variant in order to eliminate random sequencing
errors, enhancing the specificity of the technique and
reducing the computational time. To the best of knowl-
edge, our NGS method presents possibly the highest sen-
sitivity reported for NGS in AML.18,19,24-27
dPCR is a relatively novel technique for precise and
absolute quantification of nucleic acids, which is based
on limiting partitions of the PCR volume and Poisson sta-
tistics.28 It is also an extremely sensitive technique, with
a high specificity due to the detection of mutant alleles.29
However, when we compared the same standard dilu-
tions in NGS and dPCR, NGS afforded a 2-log increment
in LOQ for indels (NPM1) and a 1-log increment for SNV
(IDH1/2), with the sensitivity of dPCR for indels being
similar to that reported in a previously published study
(10-2).30 Compared with NGS, dPCR is a faster measure-
ment technique but, as it is focused, it requires allele-spe-
cific primers that can complicate the experimental proce-
dure, and a high number of parallel experiments are
needed to raise the sensitivity, which increases the cost
of the assay. Additionally, although it is possible to mul-
tiplex dPCR, unfortunately only a few targets can be
monitored simultaneously within each sample.29 Another
advantage of NGS technology is that it does not require
calibration curves in each assay, and the results are
reported in absolute values, facilitating its standardiza-
tion.  
The NGS method described here showed comparable
sensitivities (10-4 for SNV and 10-5 for indels) to those of
MFC methods in those cases with immunophenotyphi-
cally aberrant populations.10,31 Although our method had a
similar sensitivity to that of qPCR, it does not require
oligonucleotides that hybridize specifically to a particular
sequence, so all nucleotides in the amplified region can be
studied. Consequently, the NGS test is capable of detect-
ing all NPM1 subtype mutations in the same assay. 
We found positive correlations when MRD levels were
evaluated by NGS versus MFC and versus qPCR, but not
with the expected results. In the case of MFC, this could be
explained, in part, by the fact that NPM1 mutations are
E. Onecha et al.
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Table 2. Cox regression analyses.
A.
                                                                                                     Risk of death                                                                      Risk of relapse
                                                                         HR (95%CI)                              P value                                   HR (95%CI)                             P value
Sex (female vs.male)                                            1.20 (0.50–2.83)                                   0.682                                         0.94 (0.37–2.44)                                  0.906
Age per year                                                              1.04 (1.00–1.07)                                  0.013 *                                        1.03 (0.99–1.06)                                  0.069
Blasts at diagnosis (%)                                          1.00 (0.99–1.02)                                   0.667                                         1.01 (0.99–1.03)                                  0.532
Leukocytes at diagnosis (×109/L)                        1.01 (0.99–1.01)                                   0.418                                         1.00 (0.99–1.01)                                  0.508
Favorable vs. adverse ELN risk                            0.67 (0.08–5.43)                                   0.714                                         0.75 (0.09–6.00)                                  0.786
Intermediate vs. adverse ELN risk                     1.03 (0.13–7.86)                                   0.976                                         1.02 (0.13–7.82)                                  0.988
Mutated FLT3-ITD                                                    3.45 (1.40-8.52)                                  0.007 *                                        2.37 (0.86–6.51)                                  0.095
Allo-HSCT vs. intensive chemotherapy              1.35 (0.40–4.57)                                   0.634                                         1.78 (0.41–7.78)                                   0.44
Allo-HSCT vs. auto-HSCT                                       0.29 (0.05–1.74)                                   0.176                                         0.64 (0.11–3.77)                                  0.629
MRD+ by MFC                                                           2.10 (0.67–6.62)                                   0.203                                         2.40 (0.77–7.46)                                  0.130
MRD+ by qPCR                                                          2.51 (0.56–11.2)                                   0.228                                         5.01 (0.64–38.8)                                  0.123
MRD+ by NGS                                                            4.22 (1.66–10.7)                                 0.002 **                                       3.41 (1.37–8.48)                               0.008 **
B.
                                                                                                     Risk of death                                                                      Risk of relapse
                                                                         HR (95%CI)                              P value                                   HR (95%CI)                             P value
Age per year                                                             1.05  (1.02–1.09)                                 0.004 *                                       1.03  (0.99–1.07)                                  0.061
Sex (female vs.male)                                           0.84  (0.33–2.17)                                   0.720                                         1.25  (0.44–3.52)                                  0.671
Leukocytes at diagnosis (×109/L)                       1.01  (0.99–1.03)                                   0.219                                         1.07  (0.99–1.02)                                  0.481
Favorable vs. adverse ELN risk                          13.75 (0.84–226.1)                                 0.067                                       7.09 (0.37–134.15)                                0.192
Intermediate vs. adverse ELN risk                    11.22(0.82–154.2)                                  0.071                                        5.86  (0.39–86.84)                                 0.203
Mutated FLT3-ITD                                                  8.87  (2.54–30.95)                               0.001 **                                     4.18  (1.11–15.69)                               0.034*
MRD+ by NGS                                                          4.54  (1.58–13.03)                               0.005 **                                     3.76  (1.34–10.54)                               0.012*
Cox regression analyses of prognostic factors influencing the risk of relapse and risk of death of patients with acute myeloid leukemia. (A) Univariate Cox regression analysis
of each prognostic factor. (B) Multivariate Cox regression analysis evaluating the most relevant factors detected in the univariate analyses. HR: hazard ratio; 95% CI: 95% confi-
dence interval; ITD: internal tandem duplication; ELN: European LeukemiaNet; allo-HSCT: allogeneic hematopoietic stem cell transplantation; auto-HSCT: autologous hematopoi-
etic stem cell transplantation; MFC, multiparametric flow cytometry; MRD, minimal residual disease; NGS, next-generation sequencing. Statistically significant values: *P<0.05,
**P<0.01.
usually associated with monocytic subtype-AML, which
frequently presents more difficulties for identifying MRD
by MFC. Indeed, Salipante et al.27 described that the level of
success of MFC depends greatly on the immunophenotype
of the abnormal blasts and how to discriminate them from
background regenerative blasts. Moreover, due to the lack
of standardization, MFC shows substantial variability
across laboratories, including that of sample processing,
instrument configuration, number of events, and training
of pathologists.32 The lack of a strong correlation between
NGS and qPCR could be explained by the nature of the
sample (sequencing uses gDNA whereas qPCR uses
cDNA). Although RNA overexpression allows a higher
sensitivity of detection, RNA levels do not correlate with
the number of tumor cells, in contrast to mutated DNA.
Accordingly, mutated DNA is more representative of the
tumor burden than is overexpression of mutated RNA.35 It
should be noted that the prediction of survival and progres-
sion of AML using MRD NGS was better than that of the
other methodologies employed, at least in the cohorts
evaluated. 
Finally, survival analysis showed that MRD positive sta-
tus determined by NGS was associated with a higher risk
of relapse and death and that MRD negative status in post-
consolidation ssmples was associated with longer overall
and disease-free survival, in accordance with recently pub-
lished studies.23 Supporting these findings, previous studies
reported that an MRD check-point after consolidation
could be the best moment for analysis because it afforded
better prediction.8,34-37 Cox regression multivariate analyses
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Figure 4. Analysis of overall survival and disease-free survival in patients with acute myeloid leukemia stratified according to minimal residual disease levels deter-
mined by conventional methods. Kaplan-Meier plots of (A) overall survival and (B) disease-free survival according to minimal residual disease (MRD) assessment
by multiparametric flow cytometry (MRC) and (C) overall survival and (D) disease-free survival according to MRD assessment by quantitative polymerase chain reac-
tion (qPCR) analysis. The numbers of censored patients with respect to each stratified group and numbers at risk are indicated. Statistically significant values:
*P<0.05, **P<0.01.
A B
C D
confirmed that MRD positive status determined by
sequencing was the only statistically significant predictor
of the risk of relapse (P=0.012).  
In conclusion, we have optimized a new targeted
sequencing method with high sensitivity for MRD evalua-
tion with applicability in a high percentage of AML
patients, improving the capacity, over MFC or qPCR, to
predict the survival outcomes of the AML patients in our
cohort. 
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